A New Treatment Brings Hope to People with Severe Alopecia Areata
Alopecia areata is an autoimmune disease that causes sudden hair loss on the scalp, eyebrows, eyelashes, and sometimes the entire body. It affects both adults and adolescents and can have a significant psychological impact by impairing quality of life. Until recently, therapeutic options for severe forms remained limited and unsatisfactory.
An oral medication called ritlecitinib, approved since 2023, offers new prospects. This treatment works by specifically modulating certain immune system pathways involved in the destruction of hair follicles. An Italian study conducted in twenty university hospitals evaluated its efficacy and tolerability in 102 patients aged 12 and older suffering from severe alopecia areata. After 24 weeks of treatment at a dose of 50 mg per day, nearly 40% of participants experienced significant hair regrowth on the scalp, with at least 80% coverage. The results were particularly encouraging among adolescents, where nearly half responded favorably compared to only one-fifth of adults.
The improvement was not limited to the scalp. The eyebrows, eyelashes, and nails, often affected by the disease, also showed signs of recovery. Trichoscopic examinations, which allow observation of hair and scalp under magnification, confirmed a reduction in signs of inflammation and an increase in hair in the regrowth phase. At the same time, patients reported a marked improvement in their psychological well-being and daily life, with a reduction in anxiety and depression related to the disease.
Ritlecitinib proved to be generally well tolerated. The observed side effects, such as acne breakouts or headaches, remained mild and manageable. Only one case of severe anemia required discontinuation of treatment. No serious effects were reported, confirming the safety profile already observed in previous clinical trials.
This real-world study strengthens hope for people facing severe alopecia areata, especially the younger ones. It shows that ritlecitinib can restore not only hair, but also confidence and daily comfort. However, researchers emphasize the need to continue long-term observations to confirm the durability of the results and refine management strategies.
Sources
About This Study
DOI: https://doi.org/10.1007/s40257-026-01022-5
Title: Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
Journal: American Journal of Clinical Dermatology
Publisher: Springer Science and Business Media LLC
Authors: Michela Starace; Luca Rapparini; Francesca Pampaloni; Stephano Cedirian; Federico Quadrelli; Francesca Bruni; Ginevra Martelli; Giampiero Girolomoni; Francesco Bellinato; Paolo Gisondi; Giuseppe Gallo; Simone Ribero; Michela Ortoncelli; Pietro Quaglino; Luigi Gargiulo; Carlo Vignoli; Alessandra Narcisi; Francesca Ambrogio; Caterina Foti; Raffaele Dante Caposiena Caro; Iris Zalaudek; Angelo Valerio Marzano; Andrea Sechi; Mauro Barbareschi; Luca Valtellini; Silvia Mariel Ferrucci; Laura Diluvio; Enrico Matteini; Luca Bianchi; Mariateresa Cantelli; Paola Nappa; Carolina D’Elia; Valeria Boccaletti; Carola Romanò; Elisabetta Fulgione; Anna Balato; Giuseppe Argenziano; Emanuele Trovato; Elisa Cinotti; Pietro Rubegni; Federica Dall’Oglio; Francesco Lacarrubba; Giuseppe Micali; Elena Pezzolo; Francesca Caroppo; Anna Belloni Fortina; Giacomo Caldarola; Ketty Peris; Lorenzo Maria Pinto; Calogero Pagliarello; Riccardo Balestri; Carlo Tomasini; Stefania Barruscotti; Laura Atzori; Silvia Sanna; Lorenzo Ala; Giulio Bortone; Giovanni Pellacani; Alfredo Rossi; Serena Lembo; Annunziata Raimondo; Flavia Manzo Margiotta; Valentina Dini; Marco Romanelli; Andrea Megna; Francesca Prignano; Gianmarco Silvi; Oriana Simonetti; Edoardo De Simoni; Michela Magnano; Natale Schettini; Alessandro Borghi; Francesca Satolli; Maria Beatrice de Felici del Giudice; Franco Rongioletti; Stefania Guida; Gianmarco Diego Bigotto; Cesare Filippeschi; Teresa Oranges; Greta Tronconi; Bianca Maria Piraccini